Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors

Liver International

Volumn 30, Issue 10, 2010, Pages 1522-1528

  Lai, Jin Ping ^a   Sandhu, Dalbir S ^a   Yu, Chunrong ^b   Moser, Catherine D ^a   Hu, Chunling ^a   Shire, Abdirashid M ^a   Aderca, Ileana ^a   Murphy, Linda M ^a   Adjei, Alex A ^b   Sanderson, Schuyler ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Akt pathway; Apoptosis; Caspase; Heparan sulphate glycosaminoglycan (HSGAG); Heparan sulphate proteoglycan (HSPG); Oncogene; SULF2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CASPASE 7; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SULFATASE; SULFATASE 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA ISOLATION; WESTERN BLOTTING;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CYCLIN D1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFOTRANSFERASES; TRANSFECTION;

EID: 79951588078     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02336.x     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Sandhu DS, Tharayil VS, Lai JP, Roberts LR. Treatment options for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008; 2: 81-92.
3. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006; 11: 469-87.
4. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 2002; 277: 49175-85.
5. Lai J, Chien J, Staub J, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 2003; 278: 23107-17.
6. Lai J P, Chien J, Strome SE, et al. HSulf-1 modulates HGFmediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 2004; 23: 1439-47.
7. Lai JP, Chien JR, Moser DR, et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 2004; 126: 231-48.
8. Lai JP, Yu C, Moser CD, et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 2006; 130: 2130-44.
9. Li J, Kleeff J, Abiatari I, et al. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 2005; 4: 14.
10. Abiatari I, Kleeff J, Li J, et al. Hsulf-1 regulates growth and invasion of pancreatic cancer cells. J Clin Pathol 2006; 59: 1052-8.
11. Dai Y, Yang Y, Macleod V, et al. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 2005; 280: 40066-73.
12. Morimoto-Tomita M, Uchimura K, Bistrup A, et al. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 2005; 7: 1001-10.
13. Lai JP, Sandhu DS, Yu C, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008; 47: 1211-22.
14. Nawroth R, Van Zante A, Cervantes S, et al. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One 2007; 2: e392.
15. Lemjabbar-Alaoui H, Van Zante A, Singer MS, et al. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 2010; 29: 635-46.
16. Moussay E, Palissot V, Vallar L, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer 9: 115.
17. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76.
18. Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparindegrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. Future Oncol 2008; 4: 803-14.
19. Lai J, Oseini A, Moser C, et al. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent activation of the Wnt/β-catenin pathway. Hepatology 2010, in press.
20. Uchimura K, Morimoto-Tomita M, Bistrup A, et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 2006; 7: 2.
21. Ai X, Kitazawa T, Do AT, et al. SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development 2007; 134: 3327-38.
22. Adamsen BL, Kravik KL, Clausen OP, De Angelis PM. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 2007; 31: 1491-500.
23. Chau BN, Diaz RL, Saunders MA, et al. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res 2009; 69: 1368-74.
24. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12(Part 1): 679-89.
25. Siu L L, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1940-7.
26. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150-7.
27. Lai J-P, Sandhu DS, Moser C, et al. Additive effect of apicidin and doxorubicin in sulfatase 1 (SULF1)-expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol 2009; 50: 1112-21.
28. Chen KF, Yeh PY, Yeh KH, et al. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008; 68: 6698-707.
29. Hampton OA, Den Hollander P, Miller CA, et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res 2009; 19: 167-77.